Integrating neuroinflammation biomarkers into the ATN(X) framework: Advances in Alzheimer's pathogenesis, diagnosis, and insights from non‐human primate models
Alzheimer's & Dementia · 2025-08 · 21 (8)
DOI: 10.1002/alz.70472 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, online erschienen am 13.08.2025. Verfasst von Zhihui Jin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Acupuncture and Moxibustion, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Neuroinflammatory Diseases, tau Proteins. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 280 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Themen: Demenz
Abstract (Originalsprache)
The amyloid/tau/neurodegeneration (ATN) biomarker framework has greatly progressed the diagnosis and staging of Alzheimer's disease (AD). However, recent research highlights neuroinflammation as an equally critical factor in AD pathology across humans, rodents, and non‐human primates (NHPs). This review evaluates the combined use of ATN and neuroinflammatory biomarkers—such as glial fibrillary acidic protein (GFAP) (astrocytic marker) and triggering receptor expressed on myeloid cells 2 (TREM2)/ ionized calcium‐binding adapter molecule 1 (IBA‐1) (microglial markers)—in elucidating AD mechanisms, promoting early diagnosis, and shaping therapeutic strategies. It also summarizes the key features and translational potential of NHP models that closely mimic human AD pathology, highlighting the promising prospects of integrating these models with the ATN(X) biomarker system. These insights strengthen the link between biomarkers, NHP research, and clinical practice, opening new avenues for the early detection and treatment strategies of AD. Highlights Neuroinflammation biomarkers, including glial fibrillary acidic protein (GFAP), triggering receptor expressed on myeloid cells 2 (TREM2)/sTREM2, and YKL‐40, show strong clinical potential in Alzheimer's disease (AD). Incorporating neuroinflammation biomarkers into the ATN(X) framework may enhance diagnostic precision. Advanced non‐human primate (NHP) models closely replicate human brain pathology, addressing key limitations of mouse models. Measuring ATN(X) biomarkers in NHPs may improve clinical translation and support early diagnosis of AD. Optimizing NHP models—including ApoE4 status, injection protocols, and gene‐editing approaches—is crucial for reproducibility and efficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Acupuncture and Moxibustion, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China.
- Department of Neurology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, P.R. China.
- Department of Pharmacology, School of Basic Medical Sciences, Zhejiang University, Hangzhou, P.R. China.
ORCID-Profile: Huifang Tang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Jin, Z., Lu, Y., Tang, H., & Cui, H. (2025). Integrating neuroinflammation biomarkers into the ATN(X) framework: Advances in Alzheimer's pathogenesis, diagnosis, and insights from non‐human primate models. Alzheimer's & Dementia, 21(8). https://doi.org/10.1002/alz.70472
Vancouver
Jin Z, Lu Y, Tang H, Cui H. Integrating neuroinflammation biomarkers into the ATN(X) framework: Advances in Alzheimer's pathogenesis, diagnosis, and insights from non‐human primate models. Alzheimer's & Dementia. 2025;21(8). doi:10.1002/alz.70472
BibTeX
@article{Jin2025,
author = {Jin, Zhihui and Lu, Yan and Tang, Huifang and Cui, Huashun},
title = {Integrating neuroinflammation biomarkers into the ATN(X) framework: Advances in Alzheimer's pathogenesis, diagnosis, and insights from non‐human primate models},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {8},
doi = {10.1002/alz.70472}
}
EUVIMED